Albert Einstein College of Medicine

The Penn State Research Foundation

Victoria Link Limited

Steven Craig Almo

Sarah C Garrett-Thomson

Andras Fiser

Ronald D Seidel, Iii

Jonathan R Lai

Xingxing Zang

Julia Frei

Jordan M Chinai

Murali Janakiram

Tyler Grove

Brandan S Hillerich

Nina Liu

James D Love

Gary Brian Evans

Betsy C Herold

Matthew Levy

Harris Goldstein

Craig E Cameron

Natalia Cheshenko

Brian Christopher Wengerter

James J Arnold

Jeffrey Bryan Bonanno

Ron Seidel

Anthony Gizzi

Deborah Palliser

Lawrence D Harris

Rojan Shrestha

Sarah C Garrett

Rodolfo J Chaparro

Ronald D Iii Seidel

Scott J Garforth

Iii Seidel Ronald D

Rodolfo Chaparro

Disclosed are human Programmed Cell Death-1 (PD-1) receptor mutants having selectivity for PD-L1 compared to PD-L2, methods of obtaining the mutants, and uses of the mutants for treatment and imaging.

Mutant variants of PD-1 receptor with selective binding to PD-L1 and uses thereof

This document discloses a novel class of compounds for inhibiting bacterial growth and treating bacterial infection. The compounds target a key step of the futalosine pathway and therefore are effective for the selective inhibition of certain bacterial species and genera with reduced side effect in comparison with conventional antibiotics.

Compounds and methods for treatment of bacterial infections

Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD- L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

Engineered PD-1 variants

Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill HIV-infected and reactivated latent HIV-infected T cells (LHITC) to functionally cure HIV infection or improve the clinical course. Compositions and methods to increase the in vivo capacity of CD8+ T cells to kill CMV or CMV-infected cells are also provided.

Precision activation of HIV-specific CTLS to eliminate reactivated latent T cells

Methods and compositions are provided for inhibiting or treating a viral infection in a subject using cell-impermeable inhibitors of Akt, scramblase and/or a phosphatidylserine.

Prevention and treatment of viral infections

Isolated polypeptides comprising engineered mutant PD-1 polypeptide are provided, as are fusion polypeptides comprising the mutant and methods of use thereof. Bispecific PD-L1 and PD-L2 binding mutant PD-1 polypeptides are provided. PD-L2-specific binding mutant PD-1 polypeptides are also provided.

The present disclosure provides variant PD-L1 immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof

Compounds and methods for treating viral infections and reducing viral multiplication, including flaviviruses. Provided is a derivative of a compound or a pharmaceutical salt thereof, wherein the compound comprises a 3',4-didehydroribose.

Broad spectrum viral inhibitor

Methods and systems for high-throughput Identification of receptor:ligand interactions are provided. Throughout this application various publications are referred to in parentheses. Full citations for these references may be found at the end of the specification. The disclosures of these publications, and all patents, patent application publications and books referred to herein, are hereby incorporated by reference in their entirety into the subject application to more fully describe the art to which the subject invention pertains.

Methods for high throughput receptor:ligand identification

Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.

TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies

Disclosed are tumor necrosis factor receptor 1B (TNFR-1B) signaling targets and TNFR-1B mutants and their uses for treatment of diseases and disorders.

Tumor necrosis factor 1B (TNF-1B) mutants and methods of use thereof to screen for candidate therapeutic compounds

Methods and systems for high-throughput identification of receptor:ligand interactions are provided.

A composition is provided comprising an oligonucleotide aptamer conjugated to an antigen, wherein the aptamer is directed against a cell-surface target of an antigen-presenting cell. Also provided are methods of delivering an antigen to a dendritic cell and of eliciting an immune response in a subject.

Growing community of inventors

Pelham, NY, United States of America

Steven Craig Almo